Dermatology
Latest News
Dermatologists fear effects of Dobbs decision for patients on isotretinoin, methotrexate
The iPLEDGE work group has not yet issued any specific statements on the implications of the Dobbs decision on prescribing isotretinoin.
Latest News
Dermatologists embrace low-dose oral minoxidil as hair loss adjunctive therapy
The number of scholarly publications examining its use for hair loss has grown dramatically in the last two years: There were 2 in 2019, and that...
Opinion
A White female presented with pustules and erythematous macules on the left palm
A 53-year-old White female presented with itchy pustules and erythematous macules on the left palm.
Latest News
Combination of energy-based treatments found to improve Becker’s nevi
The study is the largest known case series of therapy combining 1,550-nm nonablative fractional resurfacing for patients with Becker’s nevus with...
From the Journals
IVIG proves effective for dermatomyositis in phase 3 trial
Prior to this trial, intravenous immune globulin had not been fully studied for the treatment of dermatomyositis.
Latest News
Liquid injectable silicone safe for acne scarring in dark-skinned patients, study finds
“Among the most impressive findings of our study was the permanence of effectiveness of LIS for acne scarring in patients who had treatment over a...
Latest News
Expert makes the case for not subtyping patients with rosacea
“The idea now is to take a phenotypic approach to rosacea,” Dr. Julie Harper advises.
From the Journals
Analysis of PsA guidelines reveals much room for improvement on conflicts of interest
Researchers show that a majority of the authors of the most recent psoriatic arthritis clinical practice guidelines from the American College of...
Latest News
52-week data show lebrikizumab atopic dermatitis effects maintained
ADvocate1 and ADvocate2 are two of several phase 3 trials evaluating the efficacy and safety of lebrikizumab for the treatment of atopic...
Latest News
Ruxolitinib repigments many vitiligo-affected body areas
Ruxolitinib is a Janus kinase 1/2 inhibitor that has been available for the treatment for atopic dermatitis for more than a year.
Latest News
How to handle pesky molluscum contagiosum lesions
“If you don’t treat them, they’re going to spread,” Dr. Rebecca Smith said.